Terms: = Thyroid cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Clinical Outcome
4 results:
1. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
[TBL] [Abstract] [Full Text] [Related]
2. Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
Schechter RB; Nagilla M; Joseph L; Reddy P; Khattri A; Watson S; Locati LD; Licitra L; Greco A; Pelosi G; Carcangiu ML; Lingen MW; Seiwert TY; Cohen EE
Cancer Lett; 2015 Apr; 359(2):269-74. PubMed ID: 25641339
[TBL] [Abstract] [Full Text] [Related]
3. Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.
Pelosi G; Haspinger ER; Bimbatti M; Leone G; Paolini B; Fabbri A; Tamborini E; Perrone F; Testi A; Garassino M; Maisonneuve P; de Braud F; Pilotti S; Pastorino U
Int J Surg Pathol; 2014 Apr; 22(2):136-48. PubMed ID: 24326823
[TBL] [Abstract] [Full Text] [Related]
4. Pulmonary adenocarcinoma with microcystic histology and intratumoral heterogeneity of EGFR gene polymorphism.
Yeh YC; Chou TY
Histopathology; 2010 Jul; 57(1):112-20. PubMed ID: 20653783
[TBL] [Abstract] [Full Text] [Related]
